Ab­b­Vie, Gen­mab tout ear­ly da­ta for bis­pe­cif­ic in a bid to leapfrog Re­gen­eron, Roche

One of the key drugs on which Ab­b­Vie wa­gered $750 mil­lion cash to part­ner with Gen­mab has de­liv­ered stel­lar topline re­sults, set­ting the stage for what the com­pa­nies hope will be a speedy ap­proval.

In a Phase I/II tri­al, Ab­b­Vie and Gen­mab re­port­ed a 63.1% over­all re­sponse rate among 157 re­lapsed/re­frac­to­ry large B cell lym­phoma (LB­CL) pa­tients treat­ed with ep­cori­ta­m­ab, their CD3xCD20 bis­pe­cif­ic.

Based on these re­sults, they plan to “en­gage glob­al reg­u­la­to­ry au­thor­i­ties” to dis­cuss next steps.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER